Sodium Iodide Symporter and the Radioiodine Treatment of Thyroid Carcinoma
- 26 February 2010
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nuclear Medicine and Molecular Imaging
- Vol. 44 (1), 4-14
- https://doi.org/10.1007/s13139-009-0016-1
Abstract
Since the specific accumulation of iodide in thyroid was found in 1915, radioiodine has been widely applied to diagnose and treat thyroid cancer. Iodide uptake occurs across the membrane of the thyroid follicular cells and cancer cells through an active transporter process mediated by the sodium iodide symporter (NIS). The NIS coding genes were cloned and identified from rat and human in 1996. Evaluation of the NIS gene and protein expression is critical in the management of thyroid cancer, and several approaches have been tried to increase NIS levels. Identification of the NIS gene has provided a means of expanding its role in the radionuclide gene therapy of nonthyroidal cancers as well as thyroid cancer. In this article, we explain the relationship between NIS expression and the treatment of thyroid carcinoma with I-131, and we include a review of the results of our experimental and clinical trials.Keywords
This publication has 68 references indexed in Scilit:
- Radioiodine Gene Therapy of Hepatocellular Carcinoma Targeted Human Alpha FetoproteinCancer Biotherapy & Radiopharmaceuticals, 2008
- Induction of sodium iodide symporter gene and molecular characterisation of HNF3β/FoxA2, TTF-1 and C/EBPβ in thyroid carcinoma cellsBritish Journal of Cancer, 2008
- α-Fetoprotein promoter-targeted sodium iodide symporter gene therapy of hepatocellular carcinomaGene Therapy, 2007
- Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumorsInvestigational New Drugs, 2006
- Troglitazone, the Peroxisome Proliferator-Activated Receptor-γ Agonist, Induces Antiproliferation and Redifferentiation in Human Thyroid Cancer Cell LinesThyroid®, 2005
- Genetically targeted radiotherapy for multiple myelomaBlood, 2003
- In vivo sodium iodide symporter gene therapy of prostate cancerGene Therapy, 2001
- Ref-1 Controls Pax-8 DNA-Binding ActivityBiochemical and Biophysical Research Communications, 1998
- Cloning of the Human Sodium-Iodide Symporter Promoter and Characterization in a Differentiated Human Thyroid Cell Line, KAT-50Thyroid®, 1998
- Retinoic Acid Increases Sodium/Iodide Symporter mRNA Levels in Human Thyroid Cancer Cell Lines and Suppresses Expression of Functional Symporter in Nontransformed FRTL-5 Rat Thyroid CellsBiochemical and Biophysical Research Communications, 1997